Heat‐shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double‐blind phase II study

Abstract

One-year treatment with DiaPep277 at a dosage of 1 mg is safe for use and well tolerated in children with recent-onset T1DM. However, it appears to have no beneficial effect in preserving beta-cell function or improving metabolic control.